High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.

Nae Yun Heo, Young Suk Lim, Han Chu Lee, Yung Sang Lee, Kang Mo Kim, Kwan Soo Byun, Kwang Hyub Han, Kwan Sik Lee, Seung Woon Paik, Seung Kew Yoon, Dong Jin Suh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.

Original languageEnglish
Pages (from-to)60-69
Number of pages10
JournalClinical and molecular hepatology
Volume19
Issue number1
DOIs
Publication statusPublished - 2013 Mar 1
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Clinical Trials
Intention to Treat Analysis
Therapeutics
Genotype
Protease Inhibitors
Hepacivirus
peginterferon alfa-2a

ASJC Scopus subject areas

  • Medicine(all)

Cite this

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. / Heo, Nae Yun; Lim, Young Suk; Lee, Han Chu; Lee, Yung Sang; Kim, Kang Mo; Byun, Kwan Soo; Han, Kwang Hyub; Lee, Kwan Sik; Paik, Seung Woon; Yoon, Seung Kew; Suh, Dong Jin.

In: Clinical and molecular hepatology, Vol. 19, No. 1, 01.03.2013, p. 60-69.

Research output: Contribution to journalArticle

Heo, Nae Yun ; Lim, Young Suk ; Lee, Han Chu ; Lee, Yung Sang ; Kim, Kang Mo ; Byun, Kwan Soo ; Han, Kwang Hyub ; Lee, Kwan Sik ; Paik, Seung Woon ; Yoon, Seung Kew ; Suh, Dong Jin. / High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. In: Clinical and molecular hepatology. 2013 ; Vol. 19, No. 1. pp. 60-69.
@article{41d00394b48f4753a9e9e3b68947895e,
title = "High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.",
abstract = "Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. The clinical data of 272 treatment-na{\"i}ve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81{\%} (21/26) and 55{\%} (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100{\%} (13/13) and 80{\%} (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96{\%} (24/25) and 88{\%} (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.",
author = "Heo, {Nae Yun} and Lim, {Young Suk} and Lee, {Han Chu} and Lee, {Yung Sang} and Kim, {Kang Mo} and Byun, {Kwan Soo} and Han, {Kwang Hyub} and Lee, {Kwan Sik} and Paik, {Seung Woon} and Yoon, {Seung Kew} and Suh, {Dong Jin}",
year = "2013",
month = "3",
day = "1",
doi = "10.3350/cmh.2013.19.1.60",
language = "English",
volume = "19",
pages = "60--69",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "1",

}

TY - JOUR

T1 - High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.

AU - Heo, Nae Yun

AU - Lim, Young Suk

AU - Lee, Han Chu

AU - Lee, Yung Sang

AU - Kim, Kang Mo

AU - Byun, Kwan Soo

AU - Han, Kwang Hyub

AU - Lee, Kwan Sik

AU - Paik, Seung Woon

AU - Yoon, Seung Kew

AU - Suh, Dong Jin

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.

AB - Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard peginterferon plus ribavirin therapy and the need for triple combination therapy with protease inhibitors in Koreans remain matters of debate. These issues were investigated in the present study. The clinical data of 272 treatment-naïve Korean CHC patients who were treated in a community-based clinical trial (Clinical Trial group; n=51) and in clinical practice (Cohort group; n=221), were analyzed and compared. All were treated with standard protocols of peginterferon alfa-2a plus ribavirin therapy. For patients with hepatitis C virus (HCV) genotype 1, the sustained virological response (SVR) rates in the Clinical Trial and Cohort groups were 81% (21/26) and 55% (58/106), respectively, by intention-to-treat (ITT) analysis (P=0.02), and 100% (13/13) and 80% (32/40), respectively, in treatment-adherent patients (P=0.18). For patients with HCV genotype 2, the SVR rates in these two groups were 96% (24/25) and 88% (101/115), respectively, by ITT analysis (P=0.31). Adherence and treatment duration were independent predictors of SVR for genotypes 1 and 2, respectively (P<0.01 for each). Korean patients with CHC achieved high SVR rates with peginterferon alfa-2a plus ribavirin in both the clinical trial and clinical practice settings. Measures to raise adherence to standard therapy in clinical practice may improve the SVR rates in these patients as effectively as adding protease inhibitors, thus obviating the need for the latter.

UR - http://www.scopus.com/inward/record.url?scp=84886873333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886873333&partnerID=8YFLogxK

U2 - 10.3350/cmh.2013.19.1.60

DO - 10.3350/cmh.2013.19.1.60

M3 - Article

C2 - 23593611

AN - SCOPUS:84886873333

VL - 19

SP - 60

EP - 69

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 1

ER -